Roche (RHHBY) announced the FDA has approved Alecensa for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer. The company said Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
The approval was based on positive results from the Phase III ALINA study. The company noted that the data from the Phase III ALINA study will also be used for filing submissions to additional global health authorities, including the European Medicines Agency.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.